Who We Are
What We Do
How We Do It
Where We Do It
Value, Access and Pricing
A new economic era is dawning, and understanding how value can best support price and access will be essential to the success of future and current brands.
From new modes of administration to new mechanisms of action, specialty therapeutic landscapes are crowding with new dimensions of competition. Understanding local market perceptions and behaviours are just the beginning to developing a sound commercial strategy with the expertise of CBPartners’ team.
As market and payer realities evolve, it will be essential to adapt to meet new stakeholder needs, as well as to understand the value of that adaptation.
Government Policy Advisory
The world’s landscape is quickly evolving due to both innovation and government policy. Ensuring that these policies match political and commercial goals is possible through the expertise of CBPartners’ team.
Price Transparency – Let the Light Shine
12 June 2017
Cyrus A. Chowdhury
ESRX’s New InsideRx Strategy: Cure for the Uninsured?
6 June 2017
Pipeline Optimisation: No Pain, No Gain
27 April 2017
CHN’s NRDL Update – Worth the Wait (and Heavy Discounting)?
15 March 2017
Strategic Patient Advocacy vs. Evidence Package: The “Rare” Challenge for Orphan Drug Manufacturers
28 February 2017
Is BMS Pfizer’s Next Target?
24 February 2017
Is ATM Delivering Cash in Emerging Markets?
6 February 2017
View All Blog Posts
ISPOR BOSTON: Pharmaceutical Strategic Pricing: An Analysis of Global Cross-SKU Pricing Approaches
24 May 2017
Monica Martin de Bustamante
ISPOR BOSTON: The Effectiveness of the FDA Priority Review Voucher for Neglected Tropical Diseases and Rare Pediatric Diseases
ISPOR BOSTON: Risk-Sharing Agreements (RSA) in Emerging Markets: Is it a Wake-Up Call or is it Innovation Too Late?
ISPOR BOSTON: How the Purchase and Use of a FDA Priority Review Voucher Affects Product Uptake and Value Conversion
Forecasting Failure: Learning from the Accuracy of Hindsight
ISPOR Asia 2016: Taming Enthusiasm
BREXIT: Minding the EU’s New Gap
View All White Papers